


Amendments to the Claims:

Please cancel claims 79, 80, and 125 and add new claims 126-131. Please amend claims 1-3, 9-10, 14, 16-17, 21, 26, 30-31, 35, 40, 44-45, 49, 54, 58-59, 63, 68, 72-78, 81-82, 91, 94, 97, 104, and 124 as follows.

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of Formula (I):



wherein:

R<sub>1</sub> is H or C<sub>1-3</sub> alkyl;

R<sub>2</sub> is C<sub>1-4</sub> alkyl, -CH<sub>2</sub>-O-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl or CH<sub>2</sub>OH; and

R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are each independently H, C<sub>1-4</sub> alkyl, amino, cyano, halogen, C<sub>1-4</sub> haloalkyl, nitro or OH; or

a pharmaceutically acceptable salt, hydrate [[and]] or solvate thereof,

provided that when R<sub>2</sub> is C<sub>1-4</sub> alkyl, -CH<sub>2</sub>-O-C<sub>1-4</sub> alkyl, and CH<sub>2</sub>OH then R<sub>3</sub> and R<sub>6</sub> are not both hydrogen.

2. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R<sub>1</sub> is H.

3. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_1$  is  $C_{1-8}$  alkyl.

4-8. (Canceled)

9. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_2$  is  $C_{1-4}$  alkyl.

10. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_2$  is methyl.

11-13. (Canceled)

14. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_2$  is  $C_{1-4}$  haloalkyl.

15. (Canceled)

16. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_3$  is H.

17. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_3$  is  $C_{1-4}$  alkyl.

18-20. (Canceled)

21. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_3$  is halogen.

22-25. (Canceled)

26. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_3$  is  $C_{1-4}$  haloalkyl.

27-29. (Canceled)

30. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_4$  is H.

31. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_4$  is  $C_{1-4}$  alkyl.

32-34. (Canceled)

35. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_4$  is halogen.

36-39. (Canceled)

40. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_4$  is  $C_{1-4}$  haloalkyl.

41-43. (Canceled)

44. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_5$  is H.

45. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_5$  is  $C_{1-4}$  alkyl.

46-48. (Canceled)

49. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_5$  is halogen.

50-53. (Canceled)

54. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_5$  is  $C_{1-4}$  haloalkyl.

55-57. (Canceled)

58. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_6$  is H.

59. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_6$  is  $C_{1-4}$  alkyl.

60-62. (Canceled)

63. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_6$  is halogen.

64-67. (Canceled)

68. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein  $R_6$  is  $C_{1-4}$  haloalkyl.

69-71. (Canceled)

72. (Currently amended) The compound of claim 1 selected from the group consisting of:

6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

6-Chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and

8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

73. (Currently amended) The compound of claim 1 that is 9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

74. (Currently amended) The compound of claim 1 selected from the group consisting of:

N-methyl-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and

N-methyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

75. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein said compound is an *R* enantiomer.

76. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein said compound is an *S* enantiomer.

77. (Currently amended) A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutically acceptable carrier.

78. (Currently amended) A method of ~~modulating~~ agonizing a 5HT<sub>2C</sub> receptor comprising contacting said receptor with a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

79-80. (Canceled)

81. (Currently amended) A method of treatment of a disorder ~~The method according to claim 80 wherein the disorders of the central nervous system are selected from the group consisting of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, Alzheimer disease, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, and obesity, bulimia, anorexia nervosa and premenstrual tension comprising administering to an individual in need of such treatment a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof.~~

82. (Currently Amended) The method according to claim 81 wherein the disorder of ~~the central nervous system~~ is obsesity.

83. (Canceled)

84. (Original) The method according to claim 81 wherein the sexual dysfunction is Male erectile dysfunction.

85-89. (Canceled)

90. (Currently amended) The method according to claim 82 or 84 wherein said individual is a human.

91. (Currently amended) A method of decreasing food intake of an individual comprising administering to said individual a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 77.

92. (Canceled)

93. (Previously presented) The method according to claim 91 wherein said individual is a human.

94. (Currently amended) A method of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 77.

95. (Canceled)

96. (Previously presented) The method according to claim 94 wherein said individual is a human.

97. (Currently amended) A method of controlling weight gain of an individual comprising administering to said individual suffering from weight control a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 77.

98. (Canceled)

99. (Previously presented) The method according to claim 97 wherein said individual is a human.

100-103. (Canceled)

104. (Currently amended) A method of producing a pharmaceutical composition comprising admixing at least one compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutically acceptable carrier.

105-123. (Canceled)

124. (Currently amended) The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:

R<sub>1</sub> is H, methyl, ethyl, *n*-propyl, *iso*-propyl or *n*-butyl;

R<sub>2</sub> is methyl, ethyl, *iso*-propyl, *n*-butyl or -CF<sub>3</sub>;



R<sub>3</sub> is H, -CH<sub>3</sub>, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF<sub>3</sub>, nitro or -OH;

R<sub>4</sub> is H, -CH<sub>3</sub>, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF<sub>3</sub>, nitro or -OH;

R<sub>5</sub> is H, -CH<sub>3</sub>, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF<sub>3</sub>, nitro or -OH; and

R<sub>6</sub> is H, -CH<sub>3</sub>, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF<sub>3</sub>, nitro or -OH.

125. (Canceled)

126. (New) A method of prophylaxis of a disorder selected from the group consisting of obesity, depression, anxiety disorders, psychoses, schizophrenia, and cardiovascular disorders comprising administering to an individual in need of such prophylaxis a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

127. (New) The method according to claim 126, wherein said disorder is obesity.

128. (New) The method according to claim 81, wherein said disorder is selected from the group consisting of depression and anxiety disorders.

129. (New) The method according to claim 81, wherein said disorder is selected from the group consisting of psychoses and schizophrenia.

130. (New) The method according to claim 81, wherein said disorder is epilepsy.

131. (New) The method according to claim 81, wherein said disorder is selected from drug and alcohol addiction.